Health and Fitness Health and Fitness
Tue, April 1, 2025
Mon, March 31, 2025

Eli Lilly and Novo Nordisk are tackling heart health next


Published on 2025-03-31 15:23:44 - Quartz
  Print publication without navigation

  • After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.

Eli Lilly and Novo Nordisk, known for their diabetes and obesity treatments, are now focusing on cardiovascular health. Both companies are exploring the potential of their GLP-1 receptor agonists, like Ozempic and Mounjaro, in reducing heart-related risks. These drugs, initially developed for managing blood sugar, have shown in clinical trials to also lower the risk of major adverse cardiovascular events (MACE) such as heart attacks and strokes. Eli Lilly's Mounjaro (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) are at the forefront, with ongoing studies like the SELECT trial for Wegovy, which aims to confirm cardiovascular benefits in a broader population. This shift towards heart health could expand the market for these medications, potentially transforming treatment paradigms for cardiovascular diseases.

Read the Full Quartz Article at:
[ https://www.msn.com/en-us/health/weightloss/eli-lilly-and-novo-nordisk-are-tackling-heart-health-next/ar-AA1C1fC9 ]